SEARCH

SEARCH BY CITATION

References

  • 1
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:11101115. MEDLINE
  • 2
    European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus and cyclsporin in prevention of liver allograft rejection. Lancet 1994; 344:423428. MEDLINE
  • 3
    Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et al. A randomised trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporin. N Engl J Med 1991; 23:29772983.
  • 4
    Sher LS, Cosenza CA, Michel J, Makowka L, Miller CM, Schwartz ME, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. Transplantation 1997; 64:258263. MEDLINE
  • 5
    Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11:6065. MEDLINE
  • 6
    Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, et al. Evolution of cardiovascular risk factors after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3:19. MEDLINE
  • 7
    Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 230:3;441449.
  • 8
    Charco R, Cantarell C, Vargas V, Capdevila L, Lazaro JL, Hidalgo E, et al. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg 1999; 5:204208. MEDLINE
  • 9
    Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, et al. Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK506). Liver Transpl Surg 1998; 4:328334. MEDLINE
  • 10
    Jindal R, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57:13951398. MEDLINE
  • 11
    Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > 5 years after liver transplant. Transplantation 2000; 69:781789. MEDLINE
  • 12
    Mor E, Facklam D, Hasse J, Sheiner P, Emre S, Schwartz M, et al. Weight gain and lipid profile changes in liver transplant recipients: Long-term results of the American FK506 Multicenter Study. Transplant Proc 1995; 27:1126. MEDLINE
  • 13
    Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, et al. Conversion from cyclosporin to FK506 in liver allograft recipients with cyclosporin-related complications. Transplant Proc 1990; 22:612. MEDLINE
  • 14
    Pratschke J, Neuhaus R, Tullius SG, Haller GW, Jonas S, Steinmuller T, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64:938940. MEDLINE
  • 15
    Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85:251255. MEDLINE
  • 16
    Cushman WC. The clinical significance of systolic hypertension. Am J Hypertens 1998; 11:S182S185
  • 17
    Eid A, Steffen R, Porayko MK, Beers TR, Kaese DE, Wiesner RH, et al. Beyond 1 year after liver transplantation. Mayo Clin Proc 1989; 64:446450. MEDLINE
  • 18
    Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. Arch Intern Med 1990; 150:280283. MEDLINE
  • 19
    Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55:13321339. MEDLINE
  • 20
    Textor SC, Wilson DJ, Lerman A, Romero JC, Burnett JC Jr, Wiesner R, et al. Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. Transplantation 1992; 54:7480. MEDLINE
  • 21
    Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclsporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation 1993; 56:880884. MEDLINE
  • 22
    Min DI, Chen HY, Lee MK, Ashton K, Martin MF. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacotherapy 1997; 17:457463. MEDLINE
  • 23
    Albillos A, Cacho G, Barrios C, Alvarez-Mon M, Rossi I, Gomez-Arnau J, et al. Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A-induced hnypertension. Hepatology 1998; 27:332338. MEDLINE
  • 24
    Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993; 17:355360. MEDLINE
  • 25
    Julien J, Farge D, Kreft-Jais C, Guyene TT, Plouin PF, Houssin D, et al. Cyclsporine-induced stimulationof the renin-angiotensin system after liver and heart transplantation. Transplantation 1993; 56:885891. MEDLINE
  • 26
    Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62:15881592. MEDLINE
  • 27
    Gisbert C, Prieto M, Berenguer M, Breto M, Carrasco D, de Juan M, et al. Hyperlipidaemia in liver transplant recipients: Prevalence and risk factors. Liver Transpl Surg 1997; 3:416422. MEDLINE
  • 28
    Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidaemia and obesity after orthotopic liver transplantation. Transplant Proc 1991; 23:14801483. MEDLINE
  • 29
    Stegall M, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Transplantation 1995; 60:10571060. MEDLINE
  • 30
    Munoz S. Hyperlipidaemia and other coronary risk factors after orthotopic liver transplantation: Pathogenesis, diagnosis, and management. Liver Transpl Surg 1995; 1(suppl 1):S29S38.
  • 31
    DeGroen P. Cyclosporine, low density lipoprotein, and cholesterol. Mayo Clinic Proc 1988; 63:10121021.
  • 32
    Princen HMG, Meijer P, Hofstee B, Havekes LM, Kuipers F, Vonk RJ. Effects of cyclosporine A on LDL receptor activity and bile acid synthesis in hepatocyte monolayer cultures and in vivo in the rat [abstract]. Hepatology 1987; 7:1109.
  • 33
    Abouljoud MS, Levy MF, Klintmalm GB, and the US Multicenter Study Group. Hyperlipidaemia after liver transplantation: Long-term results of the FK506/Cyclosporine A US Multicenter Trial. Transplant Proc 1995; 27:11211123. MEDLINE
  • 34
    Malekkiani N, Durand F, Bernuau JR, Heneghan MA, Tutelle-Newhall JE, Belghiti J, et al. Conversion from cyclosporin to FK506 in adult liver transplantation: Results from a North American and European series [abstract]. Hepatology 2000; 32:741.